Clinical trial

A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With…

NCT02942017 · Supernus Pharmaceuticals, Inc., Industry · Completed

Key facts

NCT number NCT02942017
Title A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
Official title A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-547 Injection in the Treatment of Adult Female Subjects With Severe Postpartum Depression and Adult Female Subjects With Moderate Postpartum Depression
Lead sponsor Supernus Pharmaceuticals, Inc., Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Postpartum Depression
Intervention type Drug
Interventions Placebo, SAGE-547 90 μg/kg/h
Enrollment 108
Start date Jul 1, 2016
Primary completion Sep 17, 2017
Completion Oct 11, 2017
First posted Oct 21, 2016
Last update posted Sep 15, 2025
Countries United States

At a glance

  • 10–99 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies